Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neoplasia and cervical carcinoma

American Journal of Clinical Pathology

Volumn 135, Issue 2, 2011, Pages 212-220

  Guo, Ming ^a   Baruch, Amy C ^b   Silva, Elvio G ^a   Jan, Yee Jee ^c   Lin, E ^a   Sneige, Nour ^a   Deavers, Michael T ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Carolinas Pathology Group   (United States)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cervical carcinoma; Cervical intraepithelial neoplasia; CIN; HPV; Human papillomavirus; P16; ProExC

Indexed keywords

ANTIBODY; PROEXC ANTIBODY; PROTEIN P16; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TUMOR MARKER; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THICKNESS; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; ADOLESCENT; ANALYTICAL EQUIPMENT; GENETICS; MIDDLE AGED; PAPILLOMA VIRUS; PATHOLOGY; STAINING; UTERINE CERVIX; UTERINE CERVIX TUMOR;

ADOLESCENT; ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PAPILLOMAVIRIDAE; REAGENT KITS, DIAGNOSTIC; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 79952274922     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP1LLX8QMDXHHO     Document Type: Article

References (28)

1. Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis. 2007;11:223-239. (Pubitemid 47530910)
2. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and metaanalysis. Lancet. 2006;367:489-498. (Pubitemid 43208905)
3. Crane JM. Pregnancy outcome after loop electrosurgical excision procedure: a systematic review. Obstet Gynecol. 2003;102(5 pt 1):1058-1062. (Pubitemid 37419997)
4. Sadler L, Saftlas A, Wang W, et al. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA. 2004;291:2100-2106. (Pubitemid 38580153)
5. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285:1500-1505. (Pubitemid 32221899)
6. McCluggage WG, Walsh MY, Thornton CM, et al. Interand intra-observer variation in the histopathological reporting of cervical squamous intraepithelial lesions using a modified Bethesda grading system. Br J Obstet Gynaecol. 1998;105:206-210. (Pubitemid 28096302)
7. Grenko RT, Abendroth CS, Frauenhoffer EE, et al. Variance in the interpretation of cervical biopsy specimens obtained for atypical squamous cells of undetermined significance. Am J Clin Pathol. 2000;114:735-740. (Pubitemid 33051909)
8. Horn LC, Reichert A, Oster A, et al. Immunostaining for p16INK4a used as a conjunctive tool improves interobserver agreement of the histologic diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2008;32:502-512. (Pubitemid 351458292)
9. Klaes R, Benner A, Friedrich T, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2002;26:1389-1399. (Pubitemid 35239415)
10. Kong CS, Balzer BL, Troxell ML, et al. p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia. Am J Surg Pathol. 2007;31:33-43. (Pubitemid 46036900)
11. Walts AE, Bose S. p16, Ki-67, and BD ProExC immunostaining: a practical approach for diagnosis of cervical intraepithelial neoplasia. Hum Pathol. 2009;40:957-964.
12. Pinto AP, Schlecht NF, Woo TY, et al. Biomarker (ProEx C, p16INK4A, and MiB-1) distinction of high-grade squamous intraepithelial lesion from its mimics. Mod Pathol. 2008;21:1067-1074.
13. Badr RE, Walts AE, Chung F, et al. BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol. 2008;32:899-906.
14. Shi J, Liu H, Wilkerson M, et al. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions. Hum Pathol. 2007;38:1335-1344. (Pubitemid 47247476)
15. Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV16-and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 2005;331:269-291. (Pubitemid 40075455)
16. Rosty C, Sheffer M, Tsafrir D, et al. Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene. 2005;24:7094-7104. (Pubitemid 41573638)
17. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16INK4A as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276-284. (Pubitemid 32225381)
18. Sano T, Masuda N, Oyama T, et al. Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia. Pathol Int. 2002;52:375-383. (Pubitemid 34748220)
19. Branca M, Ciotti M, Santini D, et al. p16INK4A expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol. 2004;23:354-365. (Pubitemid 39299024)
20. Tringler B, Gup CJ, Singh M, et al. Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol. 2004;35:689-696. (Pubitemid 38881079)
21. Hashi A, Xu JY, Kondo T, et al. p16INK4a overexpression independent of human papillomavirus infection in lobular endocervical glandular hyperplasia. Int J Gynecol Pathol. 2006;25:187-194. (Pubitemid 44620184)
22. Lei M. The MCM complex: its role in DNA replication and implications for cancer therapy. Curr Cancer Drug Targets. 2005;5:365-380. (Pubitemid 41097760)
23. Pommier Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmacol. 1993;32:103-108. (Pubitemid 23131928)
24. Gibbons D, Fogt F, Kasznica J, et al. Comparison of topoisomerase II alpha and MIB-1 expression in uterine cervical squamous lesions. Mod Pathol. 1997;10:409-413. (Pubitemid 27244225)
25. Guo M, Sneige N, Silva EG, et al. Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. Mod Pathol. 2007;20:256-266. (Pubitemid 46422181)
26. Guo M, Gong Y, Deavers M, et al. Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J Clin Microbiol. 2008;46:274-280.
27. Carreon JD, Sherman ME, Guillen D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007;26:441-446. (Pubitemid 47476331)
28. Baak JP, Kruse AJ, Janssen E, et al. Predictive testing of early CIN behaviour by molecular biomarkers. Cell Oncol. 2005;27:277-280. (Pubitemid 41831635)